Denmark-based pharmaceutical company H Lundbeck and Ovation Pharmaceuticals, a specialty pharmaceutical company, have entered into a definitive transaction agreement under which Lundbeck, through its wholly owned subsidiary Lundbeck Inc will acquire Ovation in an all cash transaction valuing Ovation at up to $900 million.
Lundbeck to acquire Ovation Pharmaceuticals